|
Jul 25
|
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
|
|
Jul 23
|
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
|
|
Jul 23
|
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
|
|
Jun 27
|
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
|
|
May 31
|
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
|
|
May 28
|
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
|
|
May 16
|
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
|
|
May 7
|
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
|
|
Apr 30
|
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
|
|
Apr 25
|
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
|
|
Apr 22
|
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
|
|
Apr 17
|
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
|
|
Apr 15
|
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
|
|
Apr 8
|
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
|
|
Apr 2
|
FSD Pharma Announces Filing of Year-End 2023 Results
|
|
Mar 27
|
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
|
|
Mar 11
|
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
|
|
Mar 5
|
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
|
|
Jan 16
|
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
|
|
Jan 11
|
GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case
|